Company intelligence / Profile preview

Zhengzhou Demai Pharmaceutical

Zhengzhou, Henan, China

Ownership: Private
Development stage: Other

Overview

Zhengzhou Demai Pharmaceutical is actively involved in generic drug development and has filed an ANDA (Abbreviated New Drug Application) with China's NMPA (National Medical Products Administration) seeking approval to market a generic version of neratinib (NERLYNX), a HER2-targeted kinase inhibitor used in breast cancer treatment.

Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Zhengzhou Demai Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhengzhou Demai Pharmaceutical.

Explore the full profile